NewLink Genetics (NASDAQ:NLNK) was downgraded by analysts at SunTrust Banks from a “buy” rating to a “hold” rating in a report released on Friday, Marketbeat.com reports.
Other research analysts have also recently issued reports about the company. Zacks Investment Research raised NewLink Genetics from a “hold” rating to a “buy” rating and set a $9.00 price target for the company in a report on Wednesday, January 3rd. Cantor Fitzgerald set a $26.00 price target on NewLink Genetics and gave the company a “buy” rating in a report on Friday. Bank of America cut their price target on NewLink Genetics from $22.00 to $18.00 and set a “buy” rating for the company in a report on Friday, March 2nd. Stifel Nicolaus reaffirmed a “buy” rating and issued a $21.00 price target (down from $25.00) on shares of NewLink Genetics in a report on Friday, March 2nd. Finally, BidaskClub raised NewLink Genetics from a “sell” rating to a “hold” rating in a report on Friday, January 5th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the company. NewLink Genetics presently has an average rating of “Hold” and a consensus price target of $20.17.
Shares of NASDAQ NLNK opened at $4.20 on Friday. NewLink Genetics has a 52-week low of $3.95 and a 52-week high of $20.47. The firm has a market cap of $271.98, a price-to-earnings ratio of -1.83 and a beta of 1.22.
Large investors have recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in NewLink Genetics by 1,823.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,269 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 9,735 shares during the last quarter. Raymond James Financial Services Advisors Inc. bought a new stake in NewLink Genetics during the 4th quarter worth about $118,000. Creative Planning bought a new stake in NewLink Genetics during the 4th quarter worth about $152,000. The Manufacturers Life Insurance Company raised its holdings in NewLink Genetics by 3.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock worth $140,000 after purchasing an additional 556 shares during the last quarter. Finally, Acadian Asset Management LLC raised its holdings in NewLink Genetics by 241.6% during the 4th quarter. Acadian Asset Management LLC now owns 19,470 shares of the biotechnology company’s stock worth $158,000 after purchasing an additional 13,770 shares during the last quarter. 65.05% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This report was posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/3340252/newlink-genetics-nlnk-rating-lowered-to-hold-at-suntrust-banks.html.
NewLink Genetics Company Profile
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.